Introduction and Highlights
The management of neovascular age-related macular degeneration (nAMD) has been revolutionized by anti-vascular endothelial growth factor (VEGF) therapies. However, polypoidal choroidal vasculopathy (PCV), a distinct clinical entity often considered a subtype of nAMD, presents unique therapeutic challenges, particularly in Asian populations where its prevalence is significantly higher. The PULSAR randomized clinical trial recently evaluated the efficacy of a high-dose (8 mg) formulation of aflibercept compared to the standard 2 mg dose. This post hoc analysis specifically scrutinizes the outcomes for the subgroup of patients diagnosed with PCV.